Small Airway Impairment and Bronchial Hyperresponsiveness in Asthma Onset.
10.4168/aair.2014.6.3.242
- Author:
Bruno SPOSATO
1
;
Marco SCALESE
;
Maria Giovanna MIGLIORINI
;
Maurizio DI TOMASSI
;
Raffaele SCALA
Author Information
1. Unit of Pneumology, "Misericordia" Hospital, Grosseto, Italy. bsposat@tin.it
- Publication Type:Original Article
- Keywords:
Airway hyperresponsiveness;
small airways;
methacholine test;
asthma;
FEF25-75;
diagnosis
- MeSH:
Asthma*;
Diagnosis;
Equidae;
Methacholine Chloride;
Risk Factors
- From:Allergy, Asthma & Immunology Research
2014;6(3):242-251
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Our study tried to find a relationship between baseline FEF25-75% and airway hyperresponsiveness (AHR) and whether a greater FEF25-75% impairment may be a marker of a more severe hyperresponsiveness in subjects with normal FEV1 and FEV1/FVC and suggestive asthma symptoms. Besides, we tried to asses a FEF25-75% cut-off value to identify hyper-reactive subjects. METHODS: 4,172 subjects (2,042 M; mean age: 38.3+/-14.9; mean FEV1 % predicted: 100.5+/-12.7 and FEV1/FVC: 85.4+/-6.8) were examined after performing a methacholine (Mch) test. All subjects reported a symptom onset within 3 years before the test. Subjects with PD20<400 or >400 microg were arbitrarily considered affected by moderate/severe and borderline AHR, respectively. RESULTS: PD20 values were 213 (IQR:86-557), 340 (IQR:157-872) and 433 (IQR:196-1032) microg in subjects with baseline FEF25-75< or =50%, FEF25-75 between 50 and 70% and FEF25-75>70% respectively (P<0.0001). Only in moderate/severe hyper-reactive subjects (excluded borderlines), PD20 was lower in the FEF25-75< or =50% subgroup than in the 1 with FEF25-75>70%. The hyperreactive subjects percentage, was higher in those with FEF25-75< or =50% and lower in those with FEF25-75>70% (P<0.0001). FEF25-75<50% (compared to FEF25-75>70%) was a higher AHR risk factor, especially in subjects with moderate/severe AHR (OR: 2.18 [IQR:1.41-3.37]; P<0.0001). Thresholds yielding the highest combined sensitivity/specificity for FEF25-75% were 75.19 (area under curve [AUC]: 0.653) and 74.95 (AUC:0.688) in subjects with PD20<2,400 and <400 microg respectively. FEV1, FVC, and FEV1/FVC measured in subjects with different FEF25-75< or =50%, FEF25-75>50 and < or =70% or FEF25-75>70% levels were similar both in normoreactive and hyperreactive subjects. CONCLUSIONS: At asthma onset, reduced baseline FEF25-75 values with normal FEV1 and FEV1/FVC may predict AHR. Detectable predictive cut-off values do not exist because even normoreactive subjects can show lower FEF25-75 values. Furthermore, a greater FEF25-75 reduction may be associated to a more severe AHR, suggesting a possible FEF25-75 role in the management of asthma when FEV1 and FEV1/FVC are normal.
